A memorandum of understanding between BioCubaFarma and the Oswaldo Cruz Foundation of Brazil stands out among the documents, which will allow the expansion of production and innovation projects for health.
The Genetic Engineering and Biotechnology and Immunoassay centers finalized protocols of intent with the Brazilian company Bahiafarma for the development of clinical studies, registration, and supply of Heberprot-P (for the treatment of diabetic foot) and rapid tests for the diagnosis of sickle cell anemia and Chagas disease.
The president of Biocubafarma, Mayda Mauri, described the exchange as very beneficial and favored the presentation of the portfolio of innovative projects and products to solve the main health problems of both nations, among which, are cancer, diabetes mellitus, and neurodegenerative diseases.
Mauri highlighted the intention to work, not only to benefit Cuba and Brazil but also other nations in the region and the African continent, so in need of the advances and results of South-South cooperation in health, economic, and biopharmaceutical industries.
The CGBBC meeting began last Monday, and was attended by the Cuban Ministers of Public Health, José Angel Portal, and of Science, Technology and Environment, Eduardo Martínez, and Vice Minister of Health of Brazil Carlos Gadhela, which allowed the reactivation of this mechanism of cooperation.
For three days, the representatives of Cuba and Brazil exchanged opinions on the importance of collaboration in health care, innovation, biotechnology, and the pharmaceutical industry and the regulation of medicines, equipment, and medical devices, focused on sustainable development that connects science and economy.
The reactivation of this mechanism, which emerged in 2011, is strategic to expand the South-South alliance in Latin America. Also, to provide technological independence for the production of goods and services intended for the health care of the most vulnerable people, strengthen the transfer of knowledge and contribute to the safeguarding of humanity.
jrr/llp/jf/crc